Logo image of PHA.CA

PREMIER HEALTH OF AMERICA IN (PHA.CA) Stock Fundamental Analysis

TSX-V:PHA - TSX Venture Exchange - CA74052G1063 - Common Stock - Currency: CAD

0.04  0 (0%)

Fundamental Rating

2

Overall PHA gets a fundamental rating of 2 out of 10. We evaluated PHA against 15 industry peers in the Health Care Providers & Services industry. PHA has a bad profitability rating. Also its financial health evaluation is rather negative. PHA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PHA had negative earnings in the past year.
PHA had a positive operating cash flow in the past year.
In multiple years PHA reported negative net income over the last 5 years.
Of the past 5 years PHA 4 years had a positive operating cash flow.
PHA.CA Yearly Net Income VS EBIT VS OCF VS FCFPHA.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

With a Return On Assets value of -25.76%, PHA is not doing good in the industry: 73.33% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -25.76%
ROE N/A
ROIC N/A
ROA(3y)-6.71%
ROA(5y)-3.2%
ROE(3y)-105.76%
ROE(5y)-61.59%
ROIC(3y)N/A
ROIC(5y)N/A
PHA.CA Yearly ROA, ROE, ROICPHA.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

PHA has a worse Gross Margin (15.92%) than 80.00% of its industry peers.
PHA's Gross Margin has declined in the last couple of years.
PHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.25%
GM growth 5Y-4.32%
PHA.CA Yearly Profit, Operating, Gross MarginsPHA.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

1

2. Health

2.1 Basic Checks

PHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHA has more shares outstanding
Compared to 5 years ago, PHA has more shares outstanding
The debt/assets ratio for PHA is higher compared to a year ago.
PHA.CA Yearly Shares OutstandingPHA.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PHA.CA Yearly Total Debt VS Total AssetsPHA.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

PHA has an Altman-Z score of 0.97. This is a bad value and indicates that PHA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PHA (0.97) is comparable to the rest of the industry.
PHA has a debt to FCF ratio of 44.99. This is a negative value and a sign of low solvency as PHA would need 44.99 years to pay back of all of its debts.
PHA has a Debt to FCF ratio (44.99) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.99
Altman-Z 0.97
ROIC/WACCN/A
WACC10.02%
PHA.CA Yearly LT Debt VS Equity VS FCFPHA.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M 25M

2.3 Liquidity

A Current Ratio of 0.54 indicates that PHA may have some problems paying its short term obligations.
PHA has a Current ratio of 0.54. This is in the lower half of the industry: PHA underperforms 60.00% of its industry peers.
PHA has a Quick Ratio of 0.54. This is a bad value and indicates that PHA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.54, PHA is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
PHA.CA Yearly Current Assets VS Current LiabilitesPHA.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for PHA have decreased strongly by -410.90% in the last year.
The Revenue has been growing slightly by 3.02% in the past year.
Measured over the past years, PHA shows a very strong growth in Revenue. The Revenue has been growing by 68.58% on average per year.
EPS 1Y (TTM)-410.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.8%
Revenue 1Y (TTM)3.02%
Revenue growth 3Y33.41%
Revenue growth 5Y68.58%
Sales Q2Q%-41.36%

3.2 Future

The Earnings Per Share is expected to grow by 11.79% on average over the next years. This is quite good.
The Revenue is expected to decrease by -5.61% on average over the next years.
EPS Next Y40.21%
EPS Next 2Y18.19%
EPS Next 3Y11.79%
EPS Next 5YN/A
Revenue Next Year-20.72%
Revenue Next 2Y-10.85%
Revenue Next 3Y-5.61%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PHA.CA Yearly Revenue VS EstimatesPHA.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
PHA.CA Yearly EPS VS EstimatesPHA.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.05 -0.05 -0.1 -0.15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

PHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHA.CA Price Earnings VS Forward Price EarningsPHA.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PHA is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
Based on the Price/Free Cash Flow ratio, PHA is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.13
EV/EBITDA 58.82
PHA.CA Per share dataPHA.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.19%
EPS Next 3Y11.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PREMIER HEALTH OF AMERICA IN

TSX-V:PHA (8/12/2025, 7:00:00 PM)

0.04

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-21 2025-05-21
Earnings (Next)08-21 2025-08-21
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners42.81%
Ins Owner ChangeN/A
Market Cap2.22M
Analysts40
Price Target0.2 (400%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33.94%
Min Revenue beat(2)-39.96%
Max Revenue beat(2)-27.91%
Revenue beat(4)0
Avg Revenue beat(4)-26.47%
Min Revenue beat(4)-39.96%
Max Revenue beat(4)-14.13%
Revenue beat(8)2
Avg Revenue beat(8)-12.94%
Revenue beat(12)2
Avg Revenue beat(12)-9.89%
Revenue beat(16)6
Avg Revenue beat(16)-0.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF 2.13
P/OCF 0.59
P/B N/A
P/tB N/A
EV/EBITDA 58.82
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)0.02
FCFY47.02%
OCF(TTM)0.07
OCFY170.69%
SpS2.42
BVpS-0.02
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.92%
FCFM 0.78%
ROA(3y)-6.71%
ROA(5y)-3.2%
ROE(3y)-105.76%
ROE(5y)-61.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.25%
GM growth 5Y-4.32%
F-Score4
Asset Turnover2.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 44.99
Debt/EBITDA 0.18
Cap/Depr 37.93%
Cap/Sales 2.05%
Interest Coverage N/A
Cash Conversion 474.34%
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z 0.97
F-Score4
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)35.11%
Cap/Depr(5y)76.64%
Cap/Sales(3y)1.6%
Cap/Sales(5y)1.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-410.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.8%
EPS Next Y40.21%
EPS Next 2Y18.19%
EPS Next 3Y11.79%
EPS Next 5YN/A
Revenue 1Y (TTM)3.02%
Revenue growth 3Y33.41%
Revenue growth 5Y68.58%
Sales Q2Q%-41.36%
Revenue Next Year-20.72%
Revenue Next 2Y-10.85%
Revenue Next 3Y-5.61%
Revenue Next 5YN/A
EBIT growth 1Y-259.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.28%
EBIT Next 3Y-11.94%
EBIT Next 5YN/A
FCF growth 1Y114.9%
FCF growth 3Y400.47%
FCF growth 5Y56.2%
OCF growth 1Y165.89%
OCF growth 3Y44.26%
OCF growth 5Y70.26%